KAZA1
MCID: KLZ004
MIFTS: 43

Kala-Azar 1 (KAZA1)

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Kala-Azar 1

MalaCards integrated aliases for Kala-Azar 1:

Name: Kala-Azar 1 57
Leishmaniasis 59 73
Leishmaniasis, Visceral, Susceptibility to, 1 57
Kala-Azar , Susceptibility to, 1 13
Kala-Azar, Susceptibility to, 1 57
Leishmaniasis, Visceral 1 57
Kaza1 57

Characteristics:

Orphanet epidemiological data:

59
leishmaniasis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-5/10000 (Worldwide); Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

OMIM 57 608207
Orphanet 59 ORPHA507
MESH via Orphanet 45 D007896
ICD10 via Orphanet 34 B55.0 B55.1 B55.2 more
UMLS via Orphanet 74 C0023281
UMLS 73 C0023281

Summaries for Kala-Azar 1

MalaCards based summary : Kala-Azar 1, also known as leishmaniasis, is related to cutaneous leishmaniasis and visceral leishmaniasis, and has symptoms including fever, pruritus and exanthema. An important gene associated with Kala-Azar 1 is KAZA1 (Kala-Azar (Visceral Leishmaniasis), Susceptibility To). Affiliated tissues include testes, skin and t cells, and related phenotypes are splenomegaly and hepatomegaly

Description from OMIM: 608207

Related Diseases for Kala-Azar 1

Diseases in the Kala-Azar 1 family:

Kala-Azar 2 Kala-Azar 3

Diseases related to Kala-Azar 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 234)
# Related Disease Score Top Affiliating Genes
1 cutaneous leishmaniasis 12.8
2 visceral leishmaniasis 12.7
3 mucocutaneous leishmaniasis 12.7
4 leishmaniasis, tegumentary 12.2
5 leishmaniasis 11.2
6 kala-azar 2 11.2
7 kala-azar 3 11.2
8 chronic rhinitis 11.1
9 trypanosomiasis 10.4
10 malaria 10.4
11 chagas disease 10.4
12 hemophagocytic lymphohistiocytosis 10.3
13 sleeping sickness 10.3
14 arthritis 10.2
15 acquired immunodeficiency syndrome 10.2
16 pancytopenia 10.2
17 rheumatoid arthritis 10.2
18 human immunodeficiency virus infectious disease 10.1
19 trypanosomiasis, human east-african 10.1
20 splenomegaly 10.1
21 lymphoma 10.1
22 hansen's disease 10.1
23 leprosy 3 10.0
24 erysipeloid 10.0
25 dermatitis 10.0
26 lupus erythematosus 10.0
27 systemic lupus erythematosus 10.0
28 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.0
29 paronychia 10.0
30 sporotrichosis 10.0
31 pulmonary tuberculosis 10.0
32 lymphopenia 10.0
33 myeloma, multiple 10.0
34 glomerulonephritis 10.0
35 leukemia 10.0
36 lepromatous leprosy 10.0
37 psoriatic arthritis 9.9
38 hepatitis 9.9
39 tuberculoid leprosy 9.9
40 filariasis 9.9
41 schistosomiasis 9.9
42 squamous cell carcinoma 9.9
43 cheilitis 9.9
44 viral infectious disease 9.9
45 acute liver failure 9.9
46 autoimmune hepatitis 9.9
47 chronic granulomatous disease 9.9
48 yaws 9.9
49 bacterial infectious disease 9.9
50 interstitial nephritis 9.9

Graphical network of the top 20 diseases related to Kala-Azar 1:



Diseases related to Kala-Azar 1

Symptoms & Phenotypes for Kala-Azar 1

Clinical features from OMIM:

608207

Human phenotypes related to Kala-Azar 1:

59 (show all 25)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 59 Very frequent (99-80%)
2 hepatomegaly 59 Very frequent (99-80%)
3 fatigue 59 Occasional (29-5%)
4 arthralgia 59 Frequent (79-30%)
5 anemia 59 Frequent (79-30%)
6 pancytopenia 59 Very frequent (99-80%)
7 pallor 59 Frequent (79-30%)
8 abnormal bleeding 59 Very frequent (99-80%)
9 weight loss 59 Frequent (79-30%)
10 elevated hepatic transaminases 59 Frequent (79-30%)
11 thrombocytopenia 59 Occasional (29-5%)
12 skin ulcer 59 Very frequent (99-80%)
13 anorexia 59 Occasional (29-5%)
14 papule 59 Very frequent (99-80%)
15 lymphadenopathy 59 Very frequent (99-80%)
16 abnormality of oral mucosa 59 Very frequent (99-80%)
17 increased antibody level in blood 59 Frequent (79-30%)
18 leukopenia 59 Occasional (29-5%)
19 abnormality of the oral cavity 59 Very frequent (99-80%)
20 skin plaque 59 Very frequent (99-80%)
21 hypoalbuminemia 59 Frequent (79-30%)
22 episodic fever 59 Very frequent (99-80%)
23 abnormality of macrophages 59 Very frequent (99-80%)
24 rhinitis 59 Very frequent (99-80%)
25 night sweats 59 Very frequent (99-80%)

UMLS symptoms related to Kala-Azar 1:


fever, pruritus, exanthema

Drugs & Therapeutics for Kala-Azar 1

Search Clinical Trials , NIH Clinical Center for Kala-Azar 1

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Kala-Azar 1

Anatomical Context for Kala-Azar 1

MalaCards organs/tissues related to Kala-Azar 1:

41
Testes, Skin, T Cells, Kidney, Bone, Myeloid, Bone Marrow

Publications for Kala-Azar 1

Articles related to Kala-Azar 1:

(show top 50) (show all 845)
# Title Authors Year
1
Gene expression profile of cytokines produced in biopsies from patients with American cutaneous leishmaniasis. ( 30273562 )
2019
2
Zoonotic Leishmaniasis, Bosnia and Herzegovina. ( 30511917 )
2019
3
Meteorological conditions, elevation and land cover as predictors for the distribution analysis of visceral leishmaniasis in Sinkiang province, Mainland China. ( 30235597 )
2019
4
DNA prime-protein boost vaccine encoding HLA-A2, HLA-A24 and HLA-DR1 restricted epitopes of CaNA2 against visceral leishmaniasis. ( 30285279 )
2019
5
Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. ( 30453246 )
2018
6
Renal dysfunction in Leishmaniasis and Chagas disease coinfection: a case report. ( 30462796 )
2018
7
In vitro antiprotozoal activity of some medicinal plants against sleeping sickness, Chagas disease and leishmaniasis. ( 30511591 )
2018
8
Effect of chaotropes in Chagas disease and leishmaniasis cross-reacting serology assays for epidemiological surveys. ( 30304274 )
2018
9
Protection of the house against Chagas disease, dengue, leishmaniasis, and lymphatic filariasis: a systematic review. ( 29074038 )
2018
10
Hybrid Molecules: Promising Compounds for the Development of New Treatments Against Leishmaniasis and Chagas Disease. ( 29521209 )
2018
11
Cheilitis: An unusual presentation of Mucocutaneous Leishmaniasis. ( 29988622 )
2018
12
Some epidemiological aspects of cutaneous leishmaniasis with emphasis on vectors and reservoirs of disease in the borderline of Iran and Iraq. ( 29844629 )
2018
13
Sandflies species composition, activity, and natural infection with Leishmania, parasite identity in lesion isolates of cutaneous leishmaniasis, central Iran. ( 29844630 )
2018
14
Modeling spatial risk of zoonotic cutaneous leishmaniasis in Central Iran. ( 29920233 )
2018
15
Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. ( 29924907 )
2018
16
Correction to: risk factors for cutaneous leishmaniasis in the rainforest of Bolivia: a cross-sectional study. ( 29950920 )
2018
17
Population Structure of Leishmania tropica Causing Anthroponotic Cutaneous Leishmaniasis in Southern Iran by PCR-RFLP of Kinetoplastid DNA. ( 29984240 )
2018
18
Accuracy of a Rapid Diagnostic Test Based on Antigen Detection for the Diagnosis of Cutaneous Leishmaniasis in Patients with Suggestive Skin Lesions in Morocco. ( 29988004 )
2018
19
Diagnosis, Treatment and Clinical Features of Cutaneous Leishmaniasis in Saudi Arabia. ( 29996626 )
2018
20
Biomarkers of Cutaneous Leishmaniasis. ( 29998089 )
2018
21
Leishmanicidal and Immunomodulatory Activities of the Palladacycle Complex DPPE 1.1, a Potential Candidate for Treatment of Cutaneous Leishmaniasis. ( 30018604 )
2018
22
Situational Analysis of Cutaneous Leishmaniasis in an Endemic Focus of the Disease, Southeastern Iran. ( 30018995 )
2018
23
Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity. ( 30026113 )
2018
24
Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions. ( 30037731 )
2018
25
Purinergic Cooperation Between P2Y2 and P2X7 Receptors Promote Cutaneous Leishmaniasis Control: Involvement of Pannexin-1 and Leukotrienes. ( 30038612 )
2018
26
A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia. ( 30044792 )
2018
27
Incidence of Endemic Human Cutaneous Leishmaniasis in the United States. ( 30046836 )
2018
28
Plasma antimony determination during cutaneous leishmaniasis treatment with intralesional infiltration of meglumine antimoniate. ( 30053341 )
2018
29
A review of cutaneous leishmaniasis in Morocco: A vertical analysisto determine appropriate interventions for control and prevention. ( 30056074 )
2018
30
Spatial modeling of cutaneous leishmaniasis in Iranian army units during 2014-2017 using a hierarchical Bayesian method and the spatial scan statistic. ( 30056641 )
2018
31
Combination of flow cytometry and qPCR to study the immune response of american cutaneous leishmaniasis patients. ( 30076983 )
2018
32
Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B. ( 30082295 )
2018
33
LACK Gene's Immune Response Induced by Cocktail DNA Vaccine with IL-12 Gene Against Cutaneous Leishmaniasis in BALB/c Mice. ( 30090205 )
2018
34
Efficacy of Apigenin and Miltefosine Combination Therapy against Experimental Cutaneous Leishmaniasis. ( 30095915 )
2018
35
Anti-tumour necrosis factor-induced cutaneous leishmaniasis in patient with psoriatic arthritis and uveitis. ( 30100239 )
2018
36
Vegetation Cover and Microspatial Distribution of Sand Flies (Diptera: Psychodidae) in an Endemic Locality for Cutaneous Leishmaniasis in Northern Argentina. ( 30113657 )
2018
37
Molecular Identification of Agents of Human Cutaneous Leishmaniasis and Canine Visceral Leishmaniasis in Different Areas of Iran Using Internal Transcribed Spacer 1 PCR-RFLP. ( 30123810 )
2018
38
Lived Experiences of Patients Suffering from Acute Old World Cutaneous Leishmaniasis: A Qualitative Content Analysis Study from Iran. ( 30123812 )
2018
39
The Potential Role of Humans in the Transmission Cycle of Leishmania major (Kinetoplastida: Trypanosomatidae), the Causative Agent of the Old World Zoonotic Cutaneous Leishmaniasis. ( 30124876 )
2018
40
Development and initial validation of a cutaneous leishmaniasis impact questionnaire. ( 30161222 )
2018
41
Cutaneous leishmaniasis and pregnancy ( 30184361 )
2018
42
Cutaneous leishmaniasis and pregnancy ( 30184376 )
2018
43
Machine learning approaches in GIS-based ecological modeling of the sand fly Phlebotomus papatasi, a vector of zoonotic cutaneous leishmaniasis in Golestan province, Iran. ( 30201488 )
2018
44
Case Report: Atypical Cutaneous Leishmaniasis in a Patient with Mixed Leishmania guyanensis and Leishmania amazonensis Infection. ( 30203744 )
2018
45
Economic Evaluation of Using Pesticides to Control Cutaneous Leishmaniasis in Isfahan. ( 30211236 )
2018
46
Cutaneous leishmaniasis in Sri Lanka: effect on quality of life. ( 30246447 )
2018
47
An Unusual Presentation of Cutaneous Leishmaniasis in 2 Canadian Patients: A Case Report. ( 30249118 )
2018
48
Miltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia. ( 30255833 )
2018
49
Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial. ( 30260376 )
2018
50
Cutaneous Leishmaniasis in a Boy from Belize. ( 30270162 )
2018

Variations for Kala-Azar 1

Expression for Kala-Azar 1

Search GEO for disease gene expression data for Kala-Azar 1.

Pathways for Kala-Azar 1

GO Terms for Kala-Azar 1

Sources for Kala-Azar 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....